澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ACDC Metals Ltd

0.049

0.000

成交量：- -

成交额：- -

市值：367.16万

市盈率：-5.20

高：0.049

开：0.049

低：0.049

收：0.049

52周最高：0.160

52周最低：0.036

股本：7,493.08万

流通股本：4,028.75万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.009

每股收益(LYR):-0.009

净资产收益率：-17.69%

总资产收益率：-8.80%

市净率：0.41

市盈率(LYR):-5.20

数据加载中...

总览公司新闻资讯公告

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ADC.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.049,"timestamp":1774501920000,"preClose":0.049,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"未开盘","change":0,"latestTime":"03-26 16:12:00 AEDT","open":0.049,"high":0.049,"low":0.049,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1774566000000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.049,"openAndCloseTimeList":[[1774479600000,1774501200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ADC.AU","preClose":0.055,"auctionPrice":0.052,"auctionVolume":5000,"auction":3,"marketStatus":"盘后竞价","timestamp":1773378384780}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-8.80%","roe":"-17.69%","lyrEps":-0.00943,"shares":74930755,"dividePrice":0,"high":0.049,"amplitude":0,"preClose":0.049,"low":0.049,"week52Low":0.036,"pbRate":"0.41","psRate":"10.66","week52High":0.16,"institutionHeld":0,"latestPrice":0.049,"eps":-0.00943,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.00943,"open":0.049,"prevYearClose":0.065,"prevWeekClose":0.049,"prevMonthClose":0.052,"prevQuarterClose":0.065,"fiveDayClose":0.049,"twentyDayClose":0.052,"sixtyDayClose":0.065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4190","ADC.AU","HR","BK4203","ADC","BC","BK4080","BK7095","BK4225","BK4231"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}